Clinical Trial Update: Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind trial of CF102 in hepatocellular carcinoma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CF102 (piclidenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-29